Marc Le Bozec

Scipio Bioscience, a Paris-based biotechnology company, provides novel sample preparation solutions for single-cell studies in the form of easy-to-use benchtop kits and intuitive, cloud-based software. Scipio Bioscience exploits a proprietary technology for barcoding for preparation of samples for single-cell profiling. The initial target of Scipio Bioscience is to provide sample preparation for single-cell transcriptomics freed of the substantial investment and running costs of existing technologies, while attaining the flexibility and scalability required in state-of-the-art research. The blooming applications in single-cell transcriptomics have revealed the importance of characterizing the diversity of cell profiles in normal tissues and cancerous tumors. For optimal results, numbers of cells in the range of thousands must be analyzed simultaneously by RNA-sequencing procedures. The costs and constraints of available methods for sample preparation have hampered widespread adoption of this approach. Scipio Bioscience overcomes these obstacles by providing a test-tube solution readily accessible to laboratories in all fields of biological research. The first outcome of this technology was the commercial release of the Asteria™ Single-cell RNA-seq Kit and its companion data analysis software Cytonaut™ in May 2022. Able to analyze 10,000 input cells in a single-tube, the kit bypasses the use of microfluidics or plate in favor of a simple, accessible protocol that is easier on cells and enables a stable stopping point 2 hours in. The resulting sequencing data can be analyzed with Cytonaut™, a cloud-based software that covers the entire 3’ scRNA-seq data analysis chain and emphasizes on the ease-of-use for biologists and bioinformaticians alike. Scipio bioscience is housed in the Paris Santé Cochin incubator, located in the celebrated Parisian Cochin Hospital.

Created in 2013, CleveXel Pharma is a pharmaceutical company with an innovative business model based on maximizing the marketing potential of disruptive molecules in exchange for a stake in the partner's equity or for the gradual purchase of a license.

NH TherAguix is a biotech company registered at RCS Grenoble and based 19, Chemin des prés, 38240 Meylan

Surgical equipment for different indications in ophthalmology and anterior segment conditions, innovative technology. Ultra-fast Femto Laser for #cataractsurgery, the only machine capable of performing a real #photoemulsification and removal of cataracted lens only with an Irrigation/aspiration cannula.

Monatomics Technology is a development stage company pioneering a novel inhalable gas mixture, consisting of xenon, helium, oxygen, and administered by a respiratory system that reduces neurotoxicity and thereby the risk of disability in acute ischemic stroke (AIS) patients. While today's Gold Standard therapies in AIS focus on the primary injury via thrombolysis and thrombectomy (or reperfusion), Monatomics focuses on the secondary injury generated by cerebral hypoxia in the ischemic penumbra via neuroprotection. The xenon acts as a neuroprotective agent by inhibiting the NMDA glutamate receptors and blocking the cascade of excitotoxicity. Monatomics' unique proprietary respiratory system recycles the xenon gas (thus making the solution commercially viable) and is scalable as it can be operated by any medical professional at any care setting - a significant hurdle in today's stroke reperfusion therapies.

CYTOO is a preclinical stage drug discovery company specialized in muscular and neuromuscular disorders. CYTOO partners its versatile patient-derived muscle drug discovery engine to pharma and biotech companies and develops its own drug candidates. CYOO has developed a fully mature human in vitro muscle model (MyoScreen) derived from primary human samples (healthy and pathological myoblasts) for generating NCEs from a variety of pathological conditions (rare, chronic). Core expertise lies on in vitro muscle regeneration, contraction, hypertrophy, and metabolism.

OSE Immunotherapeutics, a biotech dedicated to developing first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). • Tedopi® (therapeutic cancer vaccine): Registration Phase 3 in 2nd-line NSCLC in HLA-A2+ patients with secondary resistance. Phase 2 trials, sponsored by onco groups, of Tedopi® in combo in solid tumors. • Lusvertikimab (mAb IL-7R antagonist); Positive Phase 2 in UC; preclinical research in ALL. • OSE-279 (anti-PD1): 1st positive results in Phase 1/2 in solid tumors. • FR-104/VEL-101 (anti-CD28 mAb): developed in partnership with Veloxis in transplant; Phase 1/2 in renal transplant (CHU Nantes); successful Phase 1 in the US (Veloxis). • Anti-SIRPα mAb developed in partnership with Boehringer Ingelheim in advanced solid tumors & cardiovascular-renal-metabolic diseases; positive Phase 1 dose escalation results in monotherapy and combo; Phase 2 in CRM diseases planned end 2024. • ABBV-230 (ChemR23 agonist mAb) developed in partnership with AbbVie in chronic inflammation. 4 proprietary drug discovery platforms • Pro-resolutive mAb platform • Myeloid Checkpoint platform • BiCKI® Platform • mRNA Therapeutic platform f

Nicox is an international ophthalmic R&D company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare practitioners and patients around the world. Our global growth strategy is focused on outstanding international collaborations and on our proprietary programs including those from our nitric oxide-donating research platform. For more information please visit www.nicox.com

Scipio Bioscience, a Paris-based biotechnology company, provides novel sample preparation solutions for single-cell studies in the form of easy-to-use benchtop kits and intuitive, cloud-based software. Scipio Bioscience exploits a proprietary technology for barcoding for preparation of samples for single-cell profiling. The initial target of Scipio Bioscience is to provide sample preparation for single-cell transcriptomics freed of the substantial investment and running costs of existing technologies, while attaining the flexibility and scalability required in state-of-the-art research. The blooming applications in single-cell transcriptomics have revealed the importance of characterizing the diversity of cell profiles in normal tissues and cancerous tumors. For optimal results, numbers of cells in the range of thousands must be analyzed simultaneously by RNA-sequencing procedures. The costs and constraints of available methods for sample preparation have hampered widespread adoption of this approach. Scipio Bioscience overcomes these obstacles by providing a test-tube solution readily accessible to laboratories in all fields of biological research. The first outcome of this technology was the commercial release of the Asteria™ Single-cell RNA-seq Kit and its companion data analysis software Cytonaut™ in May 2022. Able to analyze 10,000 input cells in a single-tube, the kit bypasses the use of microfluidics or plate in favor of a simple, accessible protocol that is easier on cells and enables a stable stopping point 2 hours in. The resulting sequencing data can be analyzed with Cytonaut™, a cloud-based software that covers the entire 3’ scRNA-seq data analysis chain and emphasizes on the ease-of-use for biologists and bioinformaticians alike. Scipio bioscience is housed in the Paris Santé Cochin incubator, located in the celebrated Parisian Cochin Hospital.

Created in 2013, CleveXel Pharma is a pharmaceutical company with an innovative business model based on maximizing the marketing potential of disruptive molecules in exchange for a stake in the partner's equity or for the gradual purchase of a license.

NH TherAguix is a biotech company registered at RCS Grenoble and based 19, Chemin des prés, 38240 Meylan